Luca Ielasi

6PUBLICATIONS
8CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Immunology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 26, 2024
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy.

Luca Ielasi, Bernardo Stefanini, Fabio Conti

|Mar 11, 2023
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma.

Luca Ielasi, Francesco Tovoli, Matteo Tonnini

|Feb 22, 2023
Donafenib in hepatocellular carcinoma.

Rusi Chen, Luca Ielasi, Alma di Carlo

|Feb 16, 2023
TKIs in combination with immunotherapy for hepatocellular carcinoma.

Bernardo Stefanini, Luca Ielasi, Rusi Chen

|Nov 14, 2022
A case of Leishmania infection with focal splanchnic involvement without systemic symptoms: a potential anti-inflammatory role for vitamin D.

I Zaghi, L Ielasi, B Stagni

|Dec 24, 2021
Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders.

Luca Ielasi, Francesco Tovoli, Matteo Tonnini

Pageof 1

Frequent Collaborators

4 joint publications

Francesco Tovoli

4 joint publications

Alessandro Granito

3 joint publications

Rodolfo Sacco

3 joint publications

Franco Trevisani